Cargando…

Safety of direct oral anticoagulants in patients with advanced liver disease

BACKGROUND & AIMS: While direct oral anticoagulants (DOACs) are increasingly used in patients with liver disease, safety data especially in advanced chronic liver disease (ACLD) are limited. METHODS: Liver disease patients receiving DOAC treatment (ACLD: n = 104; vascular liver disease: n = 29)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Semmler, Georg, Pomej, Katharina, Bauer, David J. M., Balcar, Lorenz, Simbrunner, Benedikt, Binter, Teresa, Hartl, Lukas, Becker, Jeannette, Pinter, Matthias, Quehenberger, Peter, Trauner, Michael, Mandorfer, Mattias, Lisman, Ton, Reiberger, Thomas, Scheiner, Bernhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Cirrhosis, Liver Failure and Transplantation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456813/ https://www.ncbi.nlm.nih.gov/pubmed/34152697 http://dx.doi.org/10.1111/liv.14992

Ejemplares similares

MRI‐defined sarcopenia predicts mortality in patients with chronic liver disease
por: Beer, Lucian, et al.
Publicado: (2020)

Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Non‐invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension
por: Paternostro, Rafael, et al.
Publicado: (2020)

Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease
por: Simbrunner, Benedikt, et al.
Publicado: (2022)

Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2018)

The value of different CT‐based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis
por: Paternostro, Rafael, et al.
Publicado: (2019)

Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension
por: Paternostro, Rafael, et al.
Publicado: (2018)

Outcomes after placement of a SX‐ELLA oesophageal stent for refractory variceal bleeding—A national multicentre study
por: Pfisterer, Nikolaus, et al.
Publicado: (2018)

Fibrin clot quality in acutely ill cirrhosis patients: Relation with outcome and improvement with coagulation factor concentrates
por: Blasi, Annabel, et al.
Publicado: (2021)

Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute‐on‐chronic liver failure
por: Balcar, Lorenz, et al.
Publicado: (2021)

Renin/angiotensin system-coagulation-inflammation axis abnormalities: a possible explanation for susceptibility to severe COVID-19 in cirrhosis
por: Hartl, Lukas, et al.
Publicado: (2022)

Prediction of liver fibrosis severity in alcoholic liver disease by human microfibrillar‐associated protein 4
por: Madsen, Bjørn S., et al.
Publicado: (2020)

Low prevalence and disease severity of COVID‐19 in post‐liver transplant recipients—A single centre experience
por: Verma, Anita, et al.
Publicado: (2020)

Clinical characteristics and management of 1572 patients with pyogenic liver abscess: A 12‐year retrospective study
por: Yin, Dalong, et al.
Publicado: (2020)

Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute‐on‐chronic liver failure
por: Campello, Elena, et al.
Publicado: (2021)

Mycophenolate mofetil decreases humoral responses to three doses of SARS‐CoV‐2 vaccine in liver transplant recipients
por: Meunier, Lucy, et al.
Publicado: (2022)

Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study
por: Gitto, Stefano, et al.
Publicado: (2022)

Differential fuel utilization in liver transplant recipients and its relationship with non‐alcoholic fatty liver disease
por: Siddiqui, Mohammad S., et al.
Publicado: (2022)

Final safety and efficacy results from a 106 real‐world patients registry with an ascites‐mobilizing pump
por: Stirnimann, Guido, et al.
Publicado: (2022)

A novel score predicts mortality after transjugular intrahepatic portosystemic shunt: MOTS ‐ Modified TIPS Score
por: Fürschuß, Luisa, et al.
Publicado: (2022)

An ultrasound image‐based deep multi‐scale texture network for liver fibrosis grading in patients with chronic HBV infection
por: Ruan, Dongsheng, et al.
Publicado: (2021)

An MMP‐degraded and cross‐linked fragment of type III collagen as a non‐invasive biomarker of hepatic fibrosis resolution
por: Pehrsson, Martin, et al.
Publicado: (2022)

Effect of rifaximin on infections, acute‐on‐chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA‐AH)
por: Jiménez, César, et al.
Publicado: (2022)

Screening and surveillance of oesophageal varices in patients with HCV‐positive liver cirrhosis successfully treated by direct‐acting antiviral agents
por: Ciancio, Alessia, et al.
Publicado: (2022)

The pituitary tumour‐transforming gene 1/delta‐like homologue 1 pathway plays a key role in liver fibrogenesis
por: Perramón, Meritxell, et al.
Publicado: (2022)

The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt
por: Gioia, Stefania, et al.
Publicado: (2021)

Five‐year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study
por: Saliba, Faouzi, et al.
Publicado: (2022)

Liver growth prediction in ALPPS – A multicenter analysis from the international ALPPS registry
por: Lopez‐Lopez, Victor, et al.
Publicado: (2022)

High plasma levels of betaine, a trimethylamine N‐Oxide‐related metabolite, are associated with the severity of cirrhosis
por: van den Berg, Eline H., et al.
Publicado: (2022)

COVID‐19‐Related Downscaling of In‐Hospital Liver Care Decreased Patient Satisfaction and Increased Liver‐Related Mortality
por: Hartl, Lukas, et al.
Publicado: (2021)

Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Pomej, Katharina, et al.
Publicado: (2021)

The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2020)

Influenza A(H1N1)pdm09 vaccine effectiveness and other characteristics associated with hospitalization in chronic liver disease patients
por: Ohfuji, Satoko, et al.
Publicado: (2014)

PNPLA3 I148M (rs738409) genetic variant and age at onset of at-risk alcohol consumption are independent risk factors for alcoholic cirrhosis
por: Burza, Maria Antonella, et al.
Publicado: (2014)

Endoglin in human liver disease and murine models of liver fibrosis—A protective factor against liver fibrosis
por: Alsamman, Muhammad, et al.
Publicado: (2017)

Treatment with non‐selective beta‐blockers affects the systemic inflammatory response to bacterial DNA in patients with cirrhosis
por: Gimenez, Paula, et al.
Publicado: (2018)

Bacterascites: A study of clinical features, microbiological findings, and clinical significance
por: Oey, Rosalie C., et al.
Publicado: (2018)

Collagen type IV remodelling gender‐specifically predicts mortality in decompensated cirrhosis
por: Lehmann, Jennifer, et al.
Publicado: (2019)

Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival
por: Solé, Cristina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_se4v6md2su1pkj4fmn7hhru6gs